Literature DB >> 9563959

Allograft rejection after liver transplantation for autoimmune liver diseases.

M Hayashi1, E B Keeffe, S M Krams, O M Martinez, O N Ojogho, S K So, G Garcia, J C Imperial, C O Esquivel.   

Abstract

Autoimmune liver diseases (AILD) may progress to liver failure, requiring liver transplantation as definitive therapy, and these immune-mediated disorders may predispose the patient to more frequent graft rejection. The objective of this study was to determine the effect of preexisting AILD on the incidence of allograft rejection after liver transplantation. Sixty-three patients who underwent liver transplantation between March 1988 and December 1994 for AILDs that included autoimmune hepatitis (AIH; n = 33) and primary biliary cirrhosis (PBC; n = 30) were retrospectively compared with 47 patients who underwent liver transplantation for alcoholic cirrhosis during the same time period. There was a lower incidence of acute allograft rejection in patients with AILD who received tacrolimus-based compared with cyclosporine-based immunosuppression (50% v 85.5%; P = .02). However, patients with AILDs overall had a higher incidence of acute rejection than patients with alcoholic cirrhosis (81% v 46.8%; P < .001), regardless of the type of immunosuppression. In addition, steroid-resistant rejection occurred more frequently in patients with AILDs than in patients with alcoholic cirrhosis (38.1% v 12.8%; P = .003). There was also a trend toward a higher incidence of chronic rejection in patients with AILDs compared with patients with alcoholic cirrhosis (11.1% v 2.1%), but this difference did not reach statistical significance. Patient and graft survivals at 1 and 3 years were similar between patients with AILDs and alcoholic liver disease. Compared with alcoholic cirrhosis, preexisting AILDs are associated with a higher incidence of acute allograft rejection and a trend toward more frequent chronic rejection. Copyright 1998 W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9563959     DOI: 10.1002/lt.500040313

Source DB:  PubMed          Journal:  Liver Transpl Surg        ISSN: 1074-3022


  11 in total

1.  Impact of pretransplant antinuclear antibody and antismooth muscle antibody titers on disease recurrence and graft survival following liver transplantation in autoimmune hepatitis patients.

Authors:  Nader Dbouk; Samir Parekh
Journal:  J Gastroenterol Hepatol       Date:  2013-03       Impact factor: 4.029

2.  Outcomes in children who underwent transplantation for autoimmune hepatitis.

Authors:  Steven R Martin; Fernando Alvarez; Ravinder Anand; Changhong Song; Wanrong Yin
Journal:  Liver Transpl       Date:  2011-04       Impact factor: 5.799

3.  Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.

Authors:  A Jain; A J Demetris; R Kashyap; K Blakomer; K Ruppert; A Khan; S Rohal; T E Starzl; J J Fung
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

Review 4.  Autoimmune hepatitis--approach to diagnosis.

Authors:  Albert J Czaja
Journal:  MedGenMed       Date:  2006-05-23

5.  Autoimmune hepatitis.

Authors:  Joseph Ahn; Steven L Flamm
Journal:  Curr Treat Options Gastroenterol       Date:  2005-12

6.  Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging.

Authors:  K Blakolmer; A Jain; K Ruppert; E Gray; R Duquesnoy; N Murase; T E Starzl; J J Fung; A J Demetris
Journal:  Transplantation       Date:  2000-06-15       Impact factor: 4.939

Review 7.  Posttransplant considerations in autoimmune liver disease: Recurrence of disease and de novo.

Authors:  Alexis Gumm; Antonio Perez-Atayde; Andrew Wehrman
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-10-10

Review 8.  Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly.

Authors:  Albert J Czaja
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 9.  Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-05-06       Impact factor: 3.199

10.  Prognostic factors for the evolution and reversibility of chronic rejection in pediatric liver transplantation.

Authors:  Ana Cristina Aoun Tannuri; Fabiana Lima; Evandro Sobroza de Mello; Ryan Yukimatsu Tanigawa; Uenis Tannuri
Journal:  Clinics (Sao Paulo)       Date:  2016-04       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.